159 related articles for article (PubMed ID: 8070031)
1. Etoposide dosage and pharmacodynamics.
Joel SP; Shah R; Slevin ML
Cancer Chemother Pharmacol; 1994; 34 Suppl():S69-75. PubMed ID: 8070031
[TBL] [Abstract][Full Text] [Related]
2. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
3. Schedule-dependent topoisomerase II-inhibiting drugs.
Joel SP; Slevin ML
Cancer Chemother Pharmacol; 1994; 34 Suppl():S84-8. PubMed ID: 8070033
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacodynamics of continuous-infusion etoposide.
Miller AA; Stewart CF; Tolley EA
Cancer Chemother Pharmacol; 1990; 25(5):361-6. PubMed ID: 2155063
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
Miller AA; Tolley EA; Niell HB; Stewart CF; Griffin JP
Cancer Chemother Pharmacol; 1992; 31(2):161-6. PubMed ID: 1333371
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
9. Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.
Sessa C; Zucchetti M; Torri V; Pagani O; D'Incalci M; Gentili D; Martinelli G; deJong J; Alerci M; Cavalli F
Ann Oncol; 1993 Aug; 4(7):553-8. PubMed ID: 8395871
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
13. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.
Stewart CF
Cancer Chemother Pharmacol; 1994; 34 Suppl():S76-83. PubMed ID: 8070032
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
Higa GM; Sarkar MA; DeVore RF
Pharmacotherapy; 1999 Jan; 19(1):101-7. PubMed ID: 9917083
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
[TBL] [Abstract][Full Text] [Related]
18. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
[TBL] [Abstract][Full Text] [Related]
20. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
Desoize B; Maréchal F; Cattan A
Ann Biol Clin (Paris); 1993; 51(2):125-8. PubMed ID: 8214810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
